NCT07415005 2026-02-17
Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
Clinical Trials
11 trialsNCT05676931 2025-10-02
EDGE-Lung
Gilead Sciences
Phase 2 Active not recruiting
NCT00652561 2024-09-03
Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer
Taiho Oncology, Inc.
Phase 2 Completed
NCT04922658 2024-07-31
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Unknown
NCT05287386 2022-03-18
A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy
The First Affiliated Hospital of Xiamen University
Phase 2 Unknown
NCT00983047 2015-08-27
Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer
Biotech Pharmaceutical Co., Ltd.
Phase 2 Terminated
NCT00330746 2012-05-18
CALC-1
National Cancer Institute, Naples
Phase 2 Completed
NCT00783471 2010-06-16
DOPERLO
Hellenic Cooperative Oncology Group
Phase 2 Terminated
NCT00786331 2009-08-03
Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Unknown
NCT00161278 2008-07-30
Pilot Study for the Determination of Tumor Response to Chemotherapy in Advanced NSCLC Through Gene Expression Profiling
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00319514 2008-03-12
Weekly Versus 3-Weekly Docetaxel Plus Cisplatin for Advanced NSCLC
Gachon University Gil Medical Center
Phase 2 Completed